Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up1.00% Nasdaq Up1.29%

Affymax, Inc. (AFFY)

-Other OTC
0.64 0.00(0.31%) Apr 16, 3:59PM EDT
|Pre-Market : 1.22 Up 0.02 (1.67%) 7:58PM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Affymax, Inc.
4001 Miranda Avenue
Palo Alto, CA 94304
United States - Map
Phone: 650-812-8700
Fax: 650-424-0832

Index Membership:N/A
Full Time Employees:4

Business Summary 

Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has a strategic collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS; and a license, manufacturing, and supply agreement with Nektar Therapeutics AL Corporation to manufacture, develop, and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Affymax, Inc.

Corporate Governance 
Affymax, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 9. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 7; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Ms. Karin L. Walker , 51
Chief Accounting Officer and VP of Fin.
Dr. Anne-Marie Duliege M.D., M.S., 55
Chief Medical Officer
Mr. Richard M. Brenner , 65
Chief Exec. Officer and Director
J. Weston Rose ,
Mark G. Thompson ,
Chief Financial Officer
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders